← Back
Data updated: Jun 28, 2026
COMMAVE SUB
Pharma Pharmaceuticals
COMMAVE SUB is a pharmaceutical company with 1 FDA-approved products.
2021
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2021) 1 Novel
See 1 novel approval →
COMMAVE SUB's Key Drugs
COMMAVE SUB's core commercial portfolio centers on AZSTARYS — its most strategically important drugs approved in the last 15 years.
COMMAVE SUB's Recent FDA Approvals
New NDA/BLA approvals for COMMAVE SUB over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
COMMAVE SUB's Therapeutic Areas
Disease areas where COMMAVE SUB has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
COMMAVE SUB Pipeline Snapshot
Active clinical trials for COMMAVE SUB across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AZSTARYS leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-03-02
- Latest
- 2025-09-23
- Applications
- 1